[
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)",
    "summary": "RAHWAY, N.J., May 31, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] ≥10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined b",
    "url": "https://finnhub.io/api/news?id=03e1d444c3d86899391486f7b086ca1c38b74fae90a54f595550bba0ba2ae802",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748692800,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)",
      "id": 134918792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., May 31, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] ≥10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined b",
      "url": "https://finnhub.io/api/news?id=03e1d444c3d86899391486f7b086ca1c38b74fae90a54f595550bba0ba2ae802"
    }
  },
  {
    "ts": null,
    "headline": "Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer",
    "summary": "Merck: * KEYTRUDA® PLUS TRODELVY® REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY35% VERSUS KEYTRUDA PLUS CHEMOTHERAPY IN FIRST-LINE PD-L1+METASTATIC...",
    "url": "https://finnhub.io/api/news?id=af57a117b82ca50691a5f5072b77781185cbc8914b730cce546827bccb2436df",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748678768,
      "headline": "Merck Says Keytruda® Plus Trodelvy® Reduced Risk Of Disease Progression Or Death By 35% Versus Keytruda Plus Chemotherapy In First-Line Pd-L1+ Metastatic Triple-Negative Breast Cancer",
      "id": 134917787,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck: * KEYTRUDA® PLUS TRODELVY® REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY35% VERSUS KEYTRUDA PLUS CHEMOTHERAPY IN FIRST-LINE PD-L1+METASTATIC...",
      "url": "https://finnhub.io/api/news?id=af57a117b82ca50691a5f5072b77781185cbc8914b730cce546827bccb2436df"
    }
  }
]